Fenwick & West LLP represented Sutro Biopharma, Inc., developer of a new generation of antibody drug conjugate therapeutics and bifunctional anti-body based therapeutics for targeted cancer therapies, in its recently announced $26 million Series D financing. The round was led by Sutro Biopharma’s existing investors Alta Partners, Amgen Ventures, Celgene Corporation, Lilly Ventures, Skyline Ventures and SV Life Sciences. Since 2003, the company has raised over $90 million in funding to date.
The new investment will accelerate the development of the company’s immune-oncology portfolio with the goal of establishing next generation immuno-oncology products that will transform cancer therapy for physicians and patients. More information about Sutro Biopharma’s $26M Series D financing can be obtained from the company press release.